FDA sends its Medication Guides collection to OMB for review [marketing-compliance]
FDA announced on July 1, 2026 that a proposed information collection on Medication Guides for prescription drug products has gone to the Office of Management and Budget for review under the Paperwork Reduction Act (federalregister.gov). This is a routine PRA submission, not a new obligation, and it changes nothing about what any clinic must hand a patient today. It is worth a glance because Medication Guides are the FDA-mandated risk documents that ride along with certain prescription products, and the classes and volumes FDA cites in these submissions are a quiet read on where the agency thinks the patient-facing risk paper is heavy. No action beyond awareness, but if your dispensing touches products that carry a Medication Guide, confirm your process for delivering it is intact.
Source: federalregister.gov (2026-07-01)

Why growth outpaces compliance in healthcare startups, per DJ Holt Law [operator-intel]
DJ Holt Law argued on July 1, 2026 that direct-to-consumer prescribing networks and venture-backed wellness platforms lean on consumer-tech metrics, conversion, acquisition, recurring revenue, while the compliance infrastructure lags the growth (djholtlaw.com). This is a law firm's read on a failure mode, not a specific action, and it names the exact profile of a fast-scaling peptide or GLP-1 telehealth operation: optimizing the funnel while the licensing, supervision, and pharmacy structure stay built for an earlier, smaller version of the business. The correction the piece calls for is unglamorous, rebuild governance for the footprint you are scaling into. Before your next growth push, have counsel confirm your prescriber licensure, supervision, and pharmacy arrangements actually cover the states and volume you are selling into.
Source: djholtlaw.com (2026-07-01)

FTC conditions a $250M generic-drug deal on divestitures [marketing-compliance]
The FTC took action on June 18, 2026 requiring Aurobindo Pharma to divest four generic drug products to complete its $250 million acquisition of Lannett Company (ftc.gov). The direct subject is generic-drug competition, not compounded peptides, but the read-through matters for anyone whose margins depend on supply: the FTC is still actively conditioning pharma deals to keep generic pricing in check, which shapes the availability and cost of the products your patients ask about by name. Consolidation among the manufacturers upstream of your formulary is exactly what these orders police. Nothing lands on your desk, but track which products get divested and to whom, since that reshuffling can move availability and price in your market.
Source: ftc.gov (2026-06-18)

What regulators notice first in a healthcare investigation, per DJ Holt Law [operator-intel]
DJ Holt Law published a July 1, 2026 piece arguing that investigators weigh operational data and internal communications over polished compliance binders, and that the gap between your written protocols and your actual daily workflow is the first thing that draws scrutiny (djholtlaw.com). This is analysis, not an enforcement action, but the point is worth internalizing before you need it: a clean policy manual that no one follows is worse than useless once an investigator compares it to your records. For a peptide or HRT clinic, that gap usually lives in supervision logs, prescriber chart notes, and how staff actually route clinical decisions. Pick one core process, pull the paper trail, and see whether it matches what your policy says it should look like.
Source: djholtlaw.com (2026-07-01)

Veterans Pharmaceuticals applies to import controlled substances [compounding-bulks]
DEA published a notice on June 30, 2026 that Veterans Pharmaceuticals, Inc. has applied for registration as an importer of controlled substances (federalregister.gov). Application, not a grant, and it changes nothing on publication day; DEA review and a comment window for existing registrants come first. It is one more entry in the steady stream of importer filings worth tracking as a set, because the pattern of who is registering to move which scheduled classes is the upstream signal that eventually reaches your formulary as availability and price. Supply-chain data point, not a change to which substances a clinic may compound. If the classes named touch your suppliers, pull the notice and keep it with the others in your sourcing file.
Source: federalregister.gov (2026-06-30)

Inventory how much of your patient demand traces back to broadcast DTC advertising, and be ready to comment when the adequate-provision proposed rule posts.

Pick one core clinical process and check whether the paper trail matches your written policy.

If you run DTC prescribing at scale, book the counsel review of licensure, supervision, and pharmacy coverage before the next growth push.

Fifteen days to the July 23-24 PCAC advisory meeting: staff-briefing materials post no later than two business days before, so watch for them the week of July 21.

Agency Information Collection Activities; Submission for OMB Review; Medication Guides for Prescription Drug Products (2026-07-01, federalregister.gov)

FTC Takes Action to Protect Americans from Higher Drug Costs in Aurobindo, Lannett Deal (2026-06-18, ftc.gov)

Importer of Controlled Substances Application: Veterans Pharmaceuticals, Inc. (2026-06-30, federalregister.gov)

PCAC advisory meeting July 23-24, 2026 on seven peptides for the 503A bulks list (Federal Register 2026-07361, published 2026-04-16; docket FDA-2025-N-6895). Advisory recommendation only; FDA decides through rulemaking.

Coming Soon: Proposed Rule to Remove "Adequate Provision" (and Ban DTC TV Ads?) (thefdalawblog.com)

Why Growth Often Outpaces Compliance in Healthcare Startups (djholtlaw.com)

What Regulators Notice First During Healthcare Investigations (djholtlaw.com)

None today.